American Statistical Association
Serum tumor markers such as alphafetoprotein (AFP) and human chorionic gonadotropin (HCG) have been shown to be important in the diagnosis and management of patients with germ cell tumors. In many analyses, the rate of decline of these two markers during therapy is categorized as satisfactory or unsatisfactory based on half-life calculations and patient-specific linear regressions. There are challenges in using such categorizations. In this talk, I will talk about how variability in patient-specific half-life calculations can be adjusted for in analysis using a measurement error approach.
|Date:||Wednesday, November 20, 2013|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan-Kettering Cancer Center
Department of Epidemiology and Biostatistics
307 East 63rd Street
(between First and Second Avenues)
3rd Floor Conference Room
New York, New York
Note: To gain access to the building, please follow the directions by the telephone in the foyer.